Table 1.
Clinicopathological characteristics and treatment in recurrence-free and recurrence group.
| Recurrence | Total | Recurrence | |
|---|---|---|---|
| Mean+SD | No (N=73) | Yes (N=38) | |
| Age at diagnosis (year) | 31.3 ± 4.5 | 31.5 ± 4.5 | 31.1 ± 4.6 |
| BMI (kg/m2) | 26.6 ± 4.9 | 26.5 ± 5.0 | 26.9 ± 4.6 |
| CA125 (U/mL) | 22.5 ± 21.1 | 20.8 ± 21.7 | 25.7 ± 19.5 |
| HOMA-IR | 3.6 ± 2.7 | 3.5 ± 3.2 | 3.9 ± 1.7 |
| Glucose (mmol/L) | 5.3 ± 3.5 | 5.4 ± 4.2 | 5.1 ± 1.1 |
| Triglyceride (mmol/L) | 1.6 ± 1.1 | 1.6 ± 1.1 | 1.6 ± 1.0 |
| HDL (mmol/L) | 1.2 ± 0.4 | 1.2 ± 0.4 | 1.1 ± 0.3 |
| RCR time (month) | 3.8 ± 4.3 | NA | 7.3 ± 4.3 |
| RFS (month) | 37.5 ± 30.4 | 46.2 ± 32.1 | 20.9 ± 17.5 |
| IR | N (%) | N (%) | N (%) |
| No | 48 (43.2%) | 43 (58.9%) | 5 (13.2%) |
| Yes | 63 (56.8%) | 30 (41.1%) | 33 (86.8%) |
| MetS | |||
| No | 96 (86.5%) | 68 (93.2%) | 28 (73.7%) |
| Yes | 15 (13.5%) | 5 (6.8%) | 10 (26.3%) |
| Menstruation cycle | |||
| Regular | 56 (50.5%) | 38 (52.1%) | 18 (47.4%) |
| Irregular | 55 (49.5%) | 35 (47.9%) | 20 (52.6%) |
| Gestation | |||
| No | 63 (56.8%) | 36 (49.3%) | 27 (71.1%) |
| Yes | 48 (43.2%) | 37 (50.7%) | 11 (28.9%) |
| Parity | |||
| No | 92 (82.9%) | 57 (78.1%) | 35 (92.1%) |
| Yes | 19 (17.1%) | 16 (21.9%) | 3 (7.9%) |
| Family history | |||
| No | 98 (88.3%) | 67 (91.8%) | 31 (81.6%) |
| Yes | 13 (11.7%) | 6 (8.2%) | 7 (18.4%) |
| Hypertension | |||
| No | 103 (92.8%) | 69 (94.5%) | 34 (89.5%) |
| Yes | 8 (7.2%) | 4 (5.5%) | 4 (10.5%) |
| Diabetes | |||
| No | 87 (78.4%) | 60 (82.2%) | 27 (71.1%) |
| Yes | 24 (21.6%) | 13 (17.8%) | 11 (28.9%) |
| PCOS | |||
| No | 60 (54.1%) | 37 (50.7%) | 23 (60.5%) |
| Yes | 51 (45.9%) | 36 (49.3%) | 15 (39.5%) |
| Histological type | |||
| AEH | 63 (56.8%) | 49 (67.1%) | 14 (36.8%) |
| G1EA | 48 (43.2%) | 24 (32.9%) | 24 (63.2%) |
| Progestin type | |||
| MPA250mg | 59 (53.2%) | 36 (49.3%) | 23 (60.5%) |
| MPA500mg | 21 (18.9%) | 19 (26.0%) | 2 (5.3%) |
| MA | 17 (15.3%) | 8 (11.0%) | 9 (23.7%) |
| GnRH | 7 (6.3%) | 6 (8.2%) | 1 (2.6%) |
| ≥2 kinds | 7 (6.3%) | 4 (5.5%) | 3 (7.9%) |
| Time to CR (month) | |||
| <3 | 45 (40.5%) | 31 (42.5%) | 14 (36.8%) |
| 3-6 | 36 (32.4%) | 20 (27.4%) | 16 (42.1%) |
| >6 | 30 (27.1%) | 22 (30.1%) | 8 (21.1%) |
| Maintenance treatment after primary CR | |||
| No | 35 (31.5%) | 18 (34.6%) | 17 (44.7%) |
| Yes | 76 (68.5%) | 55 (65.4%) | 21 (55.3%) |
SD, standard deviation; BMI, body mass index; HOMA-IR, homeostasis model assessment of insulin resistance-insulin resistance; HDL, high-density lipoprotein; RCR time, complete remission time after recurrence; RFS, recurrence-free survival; IR, insulin resistance; MetS, metabolic syndrome; PCOS, polycystic ovarian syndrome; AEH, atypical endometrial hyperplasia; CR, complete remission.